Urinary Incontinence Devices and Treatments
Customize your policy alerts
Sign up for Arizona Complete Health Policy CP.MP.142 alerts
Get alerted when Policy CP.MP.142 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria and coding guidance for sacral neuromodulation (SNS/SNM) and FDA‑approved urethral bulking agents for treatment of lower urinary tract dysfunction and stress urinary incontinence for members/enrollees of the health plan.
Added language requiring use of a United States Food and Drug Administration (FDA) approved device for Sacral neuromodulation (SNM).
Updated symptom duration requirement from 12 months to at least 6 months for urinary retention.
Clarified that percutaneous stimulation test must provide at least a 50% reduction in symptoms prior to permanent SNM implantation.
Coverage Criteria: Sacral Neuromodulation and Urethral Bulking Agents
Sacral neuromodulation (trial) — Medical necessity
Covered when ALL of the following are met:
Failure of conservative measures
- Urgency/frequency or incontinence measures: For urgency/frequency or incontinence: bladder training, pelvic floor physical therapy with biofeedback, AND pharmacologic treatment
- Non‑obstructive urinary retention measures: For non‑obstructive urinary retention: intermittent self‑catheterization (unless not well tolerated) AND pharmacologic treatment
Sacral neuromodulation (permanent implantation) — Medical necessity
Covered when BOTH of the following are met:
Urethral bulking agents (UBA) — Medical necessity
Covered when ALL of the following are met:
UBA investigational/insufficient evidence
Injection of urethral bulking agents using autologous fat or non‑FDA approved procedures is not supported. The policy states there is insufficient evidence in the peer‑reviewed literature to support UBA injection of autologous fat, non‑FDA approved procedures, or uses outside the specified indications for FDA‑approved urethral bulking agents.
Evidence summaries referenced in the policy note that periurethral bulking therapies generally have lower durability and higher need for repeat treatments compared with surgical options, and that emerging approaches (for example, autologous stem‑cell or autologous fat injections) currently lack sufficient peer‑reviewed data to establish safety and effectiveness.
Coverage under this clinical policy is a guide to medical necessity and is provided subject to the terms, conditions, exclusions and limitations of the member’s coverage documents. This policy does not constitute a contract and does not guarantee payment or clinical results; final coverage determinations are governed by the applicable benefit plan, state and federal requirements, and any Health Plan administrative policies.
Use of urethral bulking injections for indications other than the policy‑specified etiologies for persistent or recurrent stress urinary incontinence (intrinsic sphincter deficiency, post‑bladder support surgery, or post‑traumatic/surgical injury) is considered unsupported. Similarly, injections employing autologous fat or other non‑FDA approved agents are considered investigational/not medically necessary due to insufficient published evidence and therefore are not covered under this policy.
Coding Guidance
| 51715 | Endoscopic injection of implant material into the submucosal tissue of the urethra and/or bladder neck. |
| 64561 | Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed. |
| 64581 | Open implantation of neurostimulator electrode array; sacral nerve (transforaminal placement). |
| 64585 | Revision or removal of peripheral neurostimulator electrode array. |
| 64590 | Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver. |
| 64595 | Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array. |
| L8679 | Implantable neurostimulator, pulse generator, any type. |
| L8680 | Implantable neurostimulator electrode, each. |
| L8681 | Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only. |
| L8682 | Implantable neurostimulator radiofrequency receiver. |
| L8683 | Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver. |
| L8684 | Radiofrequency transmitter (external) for use with implantable sacral root neurostimulator receiver for bowel and bladder management, replacement. |
| L8685 | Implantable neurostimulator pulse generator, single array, rechargeable, includes extension. |
| L8686 | Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension. |
| L8687 | Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension. |
| L8688 | Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension. |
Provider Actions, Prior Authorization, and Documentation
Prior Authorization Required
Prior Authorization is required for sacral neuromodulation (SNM) trials and permanent implantation, as well as for urethral bulking agent (UBA) injections when applicable under this policy. Submit prior authorization requests before performing trial stimulation, permanent device implantation, or UBA injection procedures.
- Affected services: SNM trial and permanent implantation; injections of FDA-approved urethral bulking agents.
Step Therapy and Sequencing Before Advanced Interventions
SNM is considered only after failure of appropriate conservative therapies. For urgency/frequency or incontinence, conservative measures include bladder training, pelvic floor physical therapy with biofeedback, and pharmacologic therapy. For non-obstructive urinary retention, conservative management includes intermittent self-catheterization (if tolerated) and pharmacologic therapy.
- SNM sequencing: trial stimulation then permanent implant only after ≥50% symptom improvement on percutaneous test.
- Conservative therapies must be attempted and documented prior to authorization requests.
Required Documentation to Support Requests
Document the clinical rationale and supporting evidence when requesting authorization. Include the member's diagnosis, symptom duration, prior conservative therapies tried (with dates and responses), results of any diagnostic testing, and the outcome of percutaneous stimulation tests (for SNM). For UBA injections, document indication (e.g., intrinsic sphincter deficiency, post-surgery), reasons surgery is contraindicated or declined, and prior conservative management.
- Required documentation: diagnosis, symptom duration ≥6 months, prior therapy details, trial stimulation response (≥50% improvement) for SNM.
- Include clinical notes, test results, and relevant procedure reports.
Check Coverage Documents and Applicable Federal/State Determinations
Coverage determinations are made in accordance with this clinical policy and are subject to the member's benefit plan, contract terms, and any applicable state or federal regulations. For Medicaid members, state Medicaid provisions take precedence over this clinical policy. For Medicare members, review applicable National and Local Coverage Determinations (NCDs/LCDs) prior to applying this policy.
- Verify member benefits, prior authorization requirements, and applicability of state Medicaid or Medicare coverage determinations before proceeding.
Denial Risk for Noncompliance with Coverage Documents
Coverage is subject to the terms, conditions, exclusions, and limitations of the member's coverage documents. Requests that do not meet the policy criteria or the member's plan terms may be denied. Providers should confirm benefit coverage, prior authorization requirements, and any plan-level administrative policies.
- Coverage may be denied if benefits do not include SNM or UBA, or if exclusions/limitations apply.
- Confirm member eligibility and coverage for the requested service prior to scheduling.
Coverage Triggers and Common Denial Reasons
Common denial reasons include: incorrect or unsupported diagnosis; insufficient duration of symptoms; inadequate documentation of failed conservative therapies; lack of documented response to a percutaneous stimulation test for SNM; and lack of justification for choosing UBA over surgical options when surgery is appropriate and acceptable to the member.
- Ensure documentation clearly shows diagnosis meets policy (e.g., non-obstructive urinary retention or overactive bladder) and symptoms present ≥6 months.
- For SNM permanent implantation, include documented ≥50% improvement on percutaneous stimulation test.
Documentation and Policy Precedence
Provider action: follow this Health Plan clinical policy and verify any applicable state Medicaid manual provisions and Medicare NCDs/LCDs that may supersede or modify coverage. When discrepancies exist between this policy and mandatory coverage rules (e.g., state Medicaid), the mandatory rules govern.
- Operational note: check the state Medicaid manual for Medicaid members; review CMS NCDs/LCDs for Medicare members.
- Contact the Health Plan for clarification when coverage conflicts arise.
Background and Clinical Context
Treatment options for urinary incontinence range from conservative, low‑risk measures to injectable and surgical interventions. Conservative therapies include behavioral strategies (bladder training), pelvic floor physical therapy with biofeedback, electrical stimulation, and pharmacologic treatment, and are preferred as first‑line approaches. Urethral bulking agents are an option for persistent or recurrent stress urinary incontinence when conservative management has failed and the member is unable to tolerate or declines surgery; these agents are typically less durable than surgical repairs and may require repeat injections. Sacral neuromodulation and other implantable neuromodulation therapies are reserved for refractory overactive bladder or non‑obstructive urinary retention after appropriate conservative measures have been tried.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.